For much of the 20th century, body fat was viewed mainly as the body’s energy reservoir—a passive tissue that stored excess calories for future use. While this remains an important function of adipose tissue, research over the past few decades has revealed a far more complex picture.
Scientists now recognize adipose tissue as a metabolically active endocrine and immune organ. It produces hormones, communicates with the brain and other organs, regulates immune activity, and plays a central role in conditions such as obesity, type 2 diabetes, cardiovascular disease, and fatty liver disease. This shift has changed how researchers and clinicians think about metabolic health, placing greater emphasis on adipose tissue function and distribution rather than body weight alone.
Moving Beyond the “Storage Depot” Model
Adipose tissue still performs essential functions including energy storage, cushioning internal organs, and providing thermal insulation. However, it is now also understood to regulate many physiological processes.
Today, fat is classified as both an endocrine organ because it secretes hormones into the bloodstream, and an immune organ because it is packed with immune cells that manage body’s defense network and regulate inflammation. Instead of a passive passenger in your metabolism, fat has been promoted to one of the drivers.
Adipose Tissue as an Endocrine Organ
A major breakthrough came in 1994 with the discovery of leptin, a hormone produced by fat cells that signals the brain about the body’s energy stores. Under normal conditions, higher fat stores increase leptin levels, helping suppress appetite and regulate energy expenditure. In many people with obesity, however, the brain becomes less responsive to leptin—a phenomenon known as leptin resistance—which contributes to impaired appetite regulation despite high circulating leptin levels.
Adipose tissue also releases many other biologically active molecules, collectively called adipokines, that influence appetite, insulin sensitivity, blood pressure, lipid metabolism, inflammation, and blood vessel function.
Among these, adiponectin plays a particularly important role. Unlike leptin, adiponectin levels usually decrease as visceral fat increases. Lower adiponectin is associated with insulin resistance, chronic inflammation, and a higher risk of cardiovascular disease.
Together, these hormones explain why changes in adipose tissue can affect the entire body—not just body weight.
The Immune Connection
Under physiological conditions, adipose tissue harbours a diverse and balanced population of resident immune cells — including regulatory T cells, anti-inflammatory macrophages, and eosinophils — that maintain tissue homeostasis.
This balance is disrupted during pathological adipose expansion. As adipocytes hypertrophy and outpace local vascular supply, areas of localised hypoxia develop within the tissue. Hypoxic and necrotic adipocytes release damage-associated molecular patterns (DAMPs) that initiate a coordinated immune response.
Monocyte-derived macrophages are recruited to the tissue and undergo polarisation toward a pro-inflammatory phenotype (M1), releasing cytokines including TNF-α and IL-6.
This creates a state of chronic, low-grade inflammation that scientists call “metaflammation” (metabolic inflammation). Unlike the acute swelling you get from a cut or infection, this simmering inflammation slowly disrupts insulin signaling. Over time, this is a primary driver of Type 2 diabetes, clogged arteries, and high blood pressure—conditions that plague millions of people.
Not All Fat Is Created Equal
The location of body fat often matters more than the total amount.
Subcutaneous fat, found beneath the skin, acts as the body’s primary energy storage site. Although excess amounts may increase body size, this fat is generally less metabolically harmful because it stores surplus energy relatively safely.
Visceral fat, which surrounds organs such as the liver and intestines, behaves very differently. It is more metabolically active and produces larger amounts of inflammatory molecules and free fatty acids that travel directly to the liver through the portal circulation. This contributes to insulin resistance, non-alcoholic fatty liver disease, abnormal cholesterol levels, and increased cardiovascular risk.
These differences help explain why two people with the same Body Mass Index (BMI) can have very different metabolic health.
Healthy vs. Unhealthy Fat Expansion
The body’s ability to store excess energy safely depends on adipogenesis, the formation of new fat cells.
When adipose tissue expands by producing many new, relatively small fat cells—a process called hyperplasia—extra energy can be stored with relatively little inflammation or metabolic disruption.
When this capacity is exceeded, existing fat cells enlarge instead, a process known as hypertrophy. Large fat cells are more likely to become oxygen-deprived, inflamed, and dysfunctional.
Eventually, excess fat begins accumulating in organs not designed for fat storage, including the liver, skeletal muscle, and heart. This ectopic fat deposition is strongly associated with insulin resistance and marks an important step toward metabolic disease.
Clinical and Research Implications
This new understanding is changing approaches to obesity and metabolic disease.
Lifestyle interventions remain fundamental. Regular physical activity can reduce visceral fat and improve insulin sensitivity even without major weight loss, while Mediterranean and plant-rich dietary patterns have been associated with lower inflammation and healthier adipokine profiles.
GLP-1 Receptor Agonists and Adipose Remodelling: GLP-1 receptor agonists such as semaglutide and tirzepatide have demonstrated efficacy that extends well beyond appetite suppression. Emerging evidence indicates these agents directly modulate adipose tissue inflammation — reducing macrophage infiltration, improving adipokine profiles, and attenuating visceral and epicardial fat depots. The degree of cardiovascular risk reduction observed in trials such as SELECT appears partly attributable to these adipose-mediated anti-inflammatory mechanisms, independent of weight loss alone.
Researchers are also investigating therapies that directly target inflammation, fibrosis, adipokine signaling, brown and beige fat activation, and adipose tissue remodeling. Although many of these approaches remain experimental, they reflect a growing shift toward improving the health of adipose tissue rather than focusing exclusively on calorie balance.
What Scientists Still Don’t Know
Despite major advances, many questions remain unanswered.
Researchers are still trying to understand why some people with obesity remain metabolically healthy while others develop diabetes or cardiovascular disease despite only modest weight gain. Scientists are also studying how ageing, sex differences, genetics, and the gut microbiome influence adipose tissue function, and whether therapies can improve adipose health independently of weight loss. Another active area of research is whether white fat can be safely converted into energy-burning brown or beige fat as a treatment for obesity and metabolic disease.
Conclusion
The traditional view of body fat as a passive energy store no longer reflects current scientific understanding. Adipose tissue is an active endocrine and immune organ that regulates metabolism, inflammation, and communication between multiple organ systems.
Whether fat supports health or contributes to disease depends not only on how much is present, but also on where it is stored, how it functions, and how it interacts with the rest of the body. As research continues, future treatments may increasingly focus on improving the health of adipose tissue itself rather than simply reducing body weight—a shift that could transform the prevention and treatment of obesity and metabolic disease.
Author Bio
